These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35667246)

  • 1. A CRISPR screen identifies redox vulnerabilities for KEAP1/NRF2 mutant non-small cell lung cancer.
    Jiang C; Ward NP; Prieto-Farigua N; Kang YP; Thalakola A; Teng M; DeNicola GM
    Redox Biol; 2022 Aug; 54():102358. PubMed ID: 35667246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
    Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
    Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thioredoxin reductase 1 inhibitor shikonin promotes cell necroptosis via SecTRAPs generation and oxygen-coupled redox cycling.
    Zhang Y; Sun S; Xu W; Yang R; Yang Y; Guo J; Ma K; Xu J
    Free Radic Biol Med; 2022 Feb; 180():52-62. PubMed ID: 34973363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
    Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
    Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer.
    Delgobo M; Gonçalves RM; Delazeri MA; Falchetti M; Zandoná A; Nascimento das Neves R; Almeida K; Fagundes AC; Gelain DP; Fracasso JI; Macêdo GB; Priori L; Bassani N; Bishop AJR; Forcelini CM; Moreira JCF; Zanotto-Filho A
    Free Radic Biol Med; 2021 Dec; 177():58-71. PubMed ID: 34673143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
    Vartanian S; Lee J; Klijn C; Gnad F; Bagniewska M; Schaefer G; Zhang D; Tan J; Watson SA; Liu L; Chen H; Liang Y; Watanabe C; Cuellar T; Kan D; Hartmaier RJ; Lau T; Costa MR; Martin SE; Merchant M; Haley B; Stokoe D
    Cancer Res; 2019 Oct; 79(19):4828-4839. PubMed ID: 31416841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
    Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
    PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
    Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
    Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
    Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.
    Paik PK; Fan PD; Qeriqi B; Namakydoust A; Daly B; Ahn L; Kim R; Plodkowski A; Ni A; Chang J; Fanaroff R; Ladanyi M; de Stanchina E; Rudin CM
    J Thorac Oncol; 2023 Apr; 18(4):516-526. PubMed ID: 36240971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plumbagin reduction by thioredoxin reductase 1 possesses synergy effects with GLUT1 inhibitor on KEAP1-mutant NSCLC cells.
    Sun S; Zhang Y; Xu W; Yang R; Yang Y; Guo J; Ma Q; Ma K; Zhang J; Xu J
    Biomed Pharmacother; 2022 Feb; 146():112546. PubMed ID: 34954641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
    Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bazedoxifene-induced ROS promote mitochondrial dysfunction and enhance osimertinib sensitivity by inhibiting the p-STAT3/SOCS3 and KEAP1/NRF2 pathways in non-small cell lung cancer.
    Meng Y; Lin W; Wang N; Wei X; Huang Q; Liao Y
    Free Radic Biol Med; 2023 Feb; 196():65-80. PubMed ID: 36646328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC.
    Ji L; Zhang R; Chen J; Xue Q; Moghal N; Tsao MS
    Sci Rep; 2019 Aug; 9(1):12437. PubMed ID: 31455821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment.
    Best SA; De Souza DP; Kersbergen A; Policheni AN; Dayalan S; Tull D; Rathi V; Gray DH; Ritchie ME; McConville MJ; Sutherland KD
    Cell Metab; 2018 Apr; 27(4):935-943.e4. PubMed ID: 29526543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.
    Jeong Y; Hellyer JA; Stehr H; Hoang NT; Niu X; Das M; Padda SK; Ramchandran K; Neal JW; Wakelee H; Diehn M
    Clin Cancer Res; 2020 Jan; 26(1):274-281. PubMed ID: 31548347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and Pathological Characteristics of
    Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J
    Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC.
    Hellyer JA; Padda SK; Diehn M; Wakelee HA
    J Thorac Oncol; 2021 Mar; 16(3):395-403. PubMed ID: 33307193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nestin regulates cellular redox homeostasis in lung cancer through the Keap1-Nrf2 feedback loop.
    Wang J; Lu Q; Cai J; Wang Y; Lai X; Qiu Y; Huang Y; Ke Q; Zhang Y; Guan Y; Wu H; Wang Y; Liu X; Shi Y; Zhang K; Wang M; Peng Xiang A
    Nat Commun; 2019 Nov; 10(1):5043. PubMed ID: 31695040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database.
    Wu Y; Yin Y; Crossland V; Vincent S; Paik PK; Lineberry N; Faller DV
    Clin Lung Cancer; 2022 Sep; 23(6):487-497. PubMed ID: 35705448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.